Hitting Refresh: How Drug Companies Use Patents to Extend Their Monopoly Power

By: Alexander Okun

  On April 17, 2025, the non-profit Initiative for Medicines, Access, and Knowledge (“I-MAK”) published a report detailing the tactics that two pharmaceutical companies use to maintain their monopolies for their popular diabetes and obesity drugs. The two drugs are Semaglutide (marketed by Novo Nordisk as Ozempic, Rybelsus, and Wegovy) and Tirzepatide (marketed by Eli Lilly as Mounjaro and Zepbound). According to I-MAK, Novo Nordisk and Eli Lilly will effectively extend their patent-based monopolies on these drugs for up to a decade. The tactic of  “patent thickets” is not new to the pharmaceutical industry, but its potential economic impact as applied to these products (known collectively as “GLP-1” drugs) could be on a scale previously unseen. Given the adverse impact this could have on US patients, the need for legal reform is greater than ever.

“Patent Thickets” and Their Uses

A US pharmaceutical patent provides 20 years of protection, after which other manufacturers can produce generic versions of the drug. However, drug companies often file an array of patents for aspects beyond the drug’s core ingredients (called a “patent thicket”) like the method of administration. Subsequent changes to the product may also get patented (known as “secondary” or “follow-on” patents) but can be as minor as adding a dose counter to the injection device. Follow-on patents can also protect purportedly “new” applications of a drug without making any changes, even though those “novel” uses were  disclosed in the initial patent. For example, Eli Lilly’s Mounjaro is approved to treat diabetes while Zepbound is approved for weight loss even though Tirzepatide’s original patent disclosed both uses.

This practice is neither novel nor unique to the GLP-1 market: a 2018 report by I-MAK found that in 2017, the top 12 grossing medications in the US had an average of 71 active patents each, extending each drug’s protection for an average of 18 years. However, the profitability of those extensions is miniscule relative to the potential with GLP-1 drugs. Whereas the top-selling drug in I-MAK’s 2018 report, Humira, produced roughly $200 billion in revenue in its first 20 years, the GLP-1 market is projected to reach $150 billion in annual revenue by 2030. Novo Nordisk has already extended its patents for Ozempic and Wegovy by five years (expiring in 2031), which I-MAK says will deliver $166 billion in additional profits. As of now, patent thickets have effectively extended the protections for Semaglutide by 10 years (expiring in 2042) and Tirzepatide by five years (expiring in 2041). 

Potential for Reform

High drug prices are a perennial issue in US politics, and two proposals appear most promising in preventing further abuses of the patent system. The first approach is to limit the number of patents that can be cited in an infringement lawsuit. This would reduce the deterrent value of patent thickets by limiting the complexity of infringement actions (therefore defendants’ costs) and reducing plaintiffs’ likelihood of succeeding. The Affordable Prescriptions For Americans Act would implement this strategy, and on April 10 it was placed on the Senate’s legislative calendar. However, some analysts say the bill’s exemptions and waivers could make it largely ineffective.

A second option is to crack down on petitions that delay the approval of generic drug versions by using the filer’s patent thickets. The “Stop STALLING Act,” would enable the Federal Trade Commission (“FTC”) to sue filers if it deems a petition “objectively baseless” and intended to “interfere with the business of a competitor.”  However, the requirement of government intervention creates greater administrative costs and potential inconsistencies in enforcement. On April 10 the Stop STALLING Act was also placed on the Senate’s legislative calendar. While both bills have potential and bipartisan sponsorship, they have failed to garner sufficient support in their past iterations. Last year the Affordable Prescriptions for Patients Act passed the Senate unanimously but was never scheduled for a vote in the House of Representatives; the Stop STALLING Act never received a vote in the Senate whatsoever. Hopefully, the resounding success of GLP-1 drugs despite their exorbitant pricing will trigger public interest broad enough to provoke Congressional action.

Puff or Pass? Supreme Court Sides With FDA in Ruling on Flavored Vapes

By: Olivia Bravo

On April 2, 2025, the Supreme Court issued a ruling that reaffirmed the Food and Drug Administration’s authority to regulate flavored e-cigarettes, denying a challenge brought by vape manufacturers. This decision is a significant landmark for administrative law and public health advocates. Why was this decision so controversial? And what does it tell us about how courts balance corporate interests with public well-being?

Background

The Food and Drug Administration (FDA) is the administrative agency responsible for overseeing the introduction of new food and drug products into interstate commerce. Before approving new products to be marketed to the general public, the FDA requires manufacturers to submit premarket applications with  “robust” scientific data for review, demonstrating that their products are “appropriate for the protection of public health.” The FDA has the specific authority to regulate the manufacture, distribution, and marketing of tobacco products under the 2009 Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act). In 2016, the Tobacco Control Act was amended under the Obama Administration to include e-cigarettes as products subject to agency review. 

Like many federal agencies, the FDA must act in accordance with the Administrative Procedure Act of 1946 (APA), which defines the limits of its regulatory authority and outlines the procedures it must follow when creating or enforcing rules. The APA, mandates transparency, consistency, and fairness in agency actions. That legal framework became central to the industry’s challenge. (See APA, 5 U.S.C. § 553). 

The Legal Challenge: FDA v. Wages and White Lion Investments, LLC

In the precursor Fifth Circuit case FDA v. Wages and White Lion Investments, LLC, plaintiffs White Lion and other manufacturers of e-cigarettes submitted to the FDA applications to market their flavored tobacco products – but were rejected for lacking long-term studies demonstrating health benefits and marketing plans that met regulatory standards. 

The companies pushed back hard, arguing that the FDA had applied inconsistent and opaque standards, effectively moving the goalposts without notice. They claimed that flavored vapes were unfairly singled out and that the FDA’s review process was arbitrary, violating the APA. They contended that this created an uneven playing field, treating flavored e-cigarettes more harshly than other tobacco products and leaving applicants to guess at the “robust standards” they needed to meet. The Fifth Circuit ultimately agreed, holding that the FDA acted outside the scope of its authority. The case was then appealed to the Supreme Court, which granted cert.

FDA Denial and Industry Pushback

What is the crux of the matter? Why did the FDA  deny the companies’ applications to sell their e-cigarettes? 

E-cigarettes and vapes are only two of the many electronic delivery system (ENDS) products that use an “e-liquid” nicotine derived from tobacco (as well as flavorings) as an aerosol that is inhaled. In this case, White Lion’s rejected products included flavors like Killer Kustard Blueberry, Rainbow Road, and Pineapple Express, sold in brightly colored packaging resembling candy or cartoons. The FDA argued that this targeted marketing posed a significant risk to youth. In the last decade, the United States has seen an explosive rise in adolescents’ vaping and the renormalization of smoking, especially among high schoolers. In 2024, 1.63 million middle and high school students used e-cigarettes. Recent statistics show that flavor is one of the most important factors adolescents consider when trying e-cigarettes for the first time. 

The vaping industry continues to frame flavored e-cigarettes as a public health innovation—a tool for adult users seeking an alternative to traditional cigarettes. Companies like Triton and Vapetasia claim their flavored vapes provide a public good by helping adult smokers quit cigarettes, with flavors making it more likely that adult smokers will transition away from combustible tobacco. However, the FDA found that e-cigarettes pose a “known and substantial” risk to youth, and concluded that the risks of bringing a new product to market outweighed any potential benefit. 

Supreme Court Review: Reversing the Fifth Circuit

Earlier this month, in the unanimous Supreme Court decision, Justice Alito agreed with the FDA that the flavored e-cigarettes and vapes proved a danger to the health of young people, writing “the kaleidoscope of flavor options adds to the allure of e-cigarettes and has thus contributed to the booming demand for such products among young Americans.” The Court found that the FDA’s actions did not violate the APA and were consistent with its regulatory responsibilities

The Supreme Court and the Fifth Circuit’s decisions differed based on their standards of procedural adherence. While the Fifth Circuit applied a stringent standard, arguing that the FDA acted arbitrarily and capriciously by shifting its standards, the Supreme Court deferred to the FDA’s expertise when no formal policy changes were in place, arguing that their decisions were not outside the scope of their authority. This divergence highlights the broader tension between judicial oversight of agency action and deference to agency expertise in complex regulatory matters, especially those that will have long-term effects on public health.

Conclusion

The Supreme Court’s decision affirms the FDA’s authority to prioritize public health and interstate commerce. In terms of implications for the vaping industry, it is clear the court has drawn the line in the sand between commercial interest and public health priorities, and set a standard for the prioritization of the youth impact over the harm to adult cigarette smokers. While this Court might have previously made different decisions concerning federal agency regulation, it is clear that the targeted health risk to youth was enough of a concern to find in favor of the FDA, whereas in another case, the Court might have gone the other direction.  

Overall, the controversy in this case was a big wake-up call for the FDA and all regulatory agencies that set guidelines for growing and advancing industries. While it might have been easier to set standards for cigarettes when the harmful effects of lung cancer were widely known, the technological and marketing advances of e-cigarettes and other alternative tobacco products have made it difficult for the FDA to keep up with both the pace of innovation and the health implications. Why leave the question of clear regulatory standards and guidelines up for interpretation? Change requirements to keep pace with the advancing world and give notice of those changes in line with transparency.  

#E-cigarettes #FDA #Regulatoryauthority #WJLTA

Reassessing In-Game IP Use: Lessons from AM General LLC v. Activision Blizzard, Inc.

By: Miranda Glisson

            Recently, I’ve developed a growing interest in car racing – particularly open-wheel, sports car, and touring car disciplines. As a result, I entered the world of Forza video games, including Forza Horizon and Forza Motorsport. While I practiced my driving skills in a not-too-fancy simulator playing Forza Motorsport, I wondered about the challenges Forza and other video games must face with licensing trademarked subject matter like cars after the AM General LLC v. Activision Blizzard, Inc. decision. 

IP Licensing in Video Games

Video games represent the pinnacle of interactive intellectual property, often requiring developers and producers to secure numerous licenses for a single game. Video game licensing refers to an agreement between a video game producer and an external company granting the producer permission to use the company’s intellectual property in their game. Game producers may employ licenses to use copyrighted and trademarked works in their games.

            Video game producers and external companies negotiate and agree upon each license.  Each license can have differing stipulations depending on how an external company wants their copyrighted or trademarked logo/work used within the game, ensuring the user’s perception of the external company’s work aligns with that company’s desire in how they are perceived.

Video game developers may want to obtain permission to use a third party’s trademark in their game to bring their creative vision to life. Incorporating trademarks from other companies can enhance realism, enable parody, or support commentary. However, obtaining the permission to use a trademark in a video game varies in difficulty, and the licenses can boast specific terms and conditions regarding use, scope, duration, quality control, and fees.

AM General LLC v. Activision Blizzard, Inc.

Trademark licenses may not be required when video game developers use the trademarked subject matter artistically or expressively. When one’s trademark is used in an artistic or expressive way by another, courts have narrowly interpreted the Lanham Act (the primary federal statute governing trademark law in the United States) to avoid suppressing protected speech under the First Amendment. In AM General LLC v. Activision Blizzard, Inc., AM General brought a trademark infringement claim against Activision Blizzard for using Humvees in their game, Call of Duty, without obtaining permission. The court determined the inclusion of Humvees in the game was intended to enhance realism, deeming their use as an expressive form of creativity. As a result, Activision Blizzard was within its rights to incorporate real-world subjects for artistic purposes and thus did not infringe upon AM General’s trademark.

AM General LLC v. Activision Blizzard, Inc. had significant impacts on video game licensing by establishing that real-world objects that are depicted in video games enhance artistic realism are protected under the First Amendment. As a result, video game developers do not need to obtain a license from trademark holders if the use is to enhance artistic realism. However, it is unclear how far the holding of AM General LLC v. Activision Blizzard, Inc. reaches. A major factor in the AM General LLC v. Activision Blizzard, Inc. decision was that consumer confusion was unlikely between the plaintiff’s Humvees and the defendant’s game, as there was no evidence of significant market overlap or direct competition. Accordingly, it would be expected that if there was market or consumer overlap between one party’s work and the other’s trademark, there would not be protected use of that mark, and therefore, a license would be required.

            I, as a very novice video game player, enjoy video games’ depictions of realism as it enhances immersion. As video games incorporate brands and products into their games to enhance realism, developers are required to navigate when trademark licensing agreements are required or not. Decisions like AM General LLC v. Activision Blizzard, Inc. show that trademarks can be used if they are for artistic or expressive purposes, if there is little likelihood of consumer confusion. However, this boundary is uncertain and likely creates difficulty for video game developers as, ultimately, video games are a mix of art, collaboration, and commerce, creating difficult intellectual property challenges.

#videogames #artisticrealism #trademarks

Diarra v. FIFA: A Clash Between Global Sports Governance and Individual Labor Rights

By: Tavis McClain

When a footballer challenges the most powerful governing body in sports, the world pays attention. Lassana Diarra, a talented midfielder, has entered into a stand-off with the very institution meant to uphold the spirit of the game. This case incited intense debate on fairness, freedom, and the balance of power in professional football.

Introduction

Diarra v. FIFA challenges the foundational structures of sports governance. This dispute raises crucial questions about how international sports bodies govern, how athletes assert their rights, and where the boundaries lie between sporting rules and fundamental labor protections. The situation is emblematic of a deeper tension in modern sport: the power of centralized global institutions like FIFA versus the rights of individuals navigating the professional system. It reveals a crucial lens into how the governance of international sport must adapt in response to legal, ethical, and human rights standards.

Background

Lassana Diarra, a well-regarded French international, terminated his contract with Russian club Lokomotiv Moscow in 2014. Diarra claimed the club had breached the contract by failing to pay his wages and creating a hostile work environment. However, FIFA’s Dispute Resolution Chamber (DRC) ruled Diarra had no just cause for the termination as there wasn’t sufficient evidence of a breach by Lokomotiv Moscow. FIFA subsequently imposed a fine and a global playing ban until the compensation was paid—a punishment that effectively paused Diarra’s career and forced him out of the game.

FIFA’s Ruling and CAS Appeal

Diarra appealed to the Court of Arbitration for Sport (CAS), which largely upheld FIFA’s decision. Decisions from the CAS are generally considered binding on FIFA as well as other institutions. The CAS ruling emphasized the principle of contractual stability in football—a cornerstone of FIFA’s regulations, designed to prevent players and clubs from breaching agreements unilaterally. Diarra subsequently challenged the ban in French civil courts, arguing that the enforcement of FIFA’s decision within national jurisdiction violated his fundamental labor rights, particularly his right to work.

Global Sports Governance Under Scrutiny

FIFA, as the global governing body of football, enforces a centralized dispute resolution system designed to streamline legal matters and preserve uniformity across jurisdictions. This case, however, exposes the limitations of that model:

  • Enforcement Without Borders: FIFA’s global ban extended beyond Russia, restricting Diarra’s ability to play in any league worldwide. This reveals how sports governing bodies can bypass national labor protections through international enforcement.
  • Lack of Worker Protections: FIFA’s mechanisms often prioritize contractual order over employee rights, a model that may not always align with domestic labor standards, especially within the EU.
  • Limited Transparency and Appeal: The CAS arbitration system, while designed for expediency, is often criticized for its lack of transparency, limited recourse, and the asymmetry in power between athletes and governing bodies.

What This Means for Labor Rights in Sport

  1. The Right to Just Cause
    The case demonstrates how difficult it can be for players to assert just cause in contract disputes, especially when proving workplace mistreatment or unpaid wages. It sparks questions about the fairness of a system where players are held to stricter standards than employers. Players are forced to prove they were not fired for a legitimate purpose, while FIFA is not required to present evidence.
  2. Access to National Legal Systems
    Diarra’s recourse to the French courts signaled that national jurisdictions can and will challenge the authority of sports bodies when fundamental rights are at stake. This could set a precedent for athletes bypassing arbitration if labor rights are seen to be compromised. If FIFA does not provide relief when its players have their labor rights violated, then they will seek alternative routes of action. It is in the interest of FIFA and the players to settle these conflicts on their behalf to reduce transaction costs and promote transparency.
  3. Rethinking the Role of CAS
    As the de facto “supreme court” of sports, CAS must adapt its structure to better balance institutional interests with individual protections. The current structure favors institutional interests over those of the individual. This may include more transparent hearings, greater independence, and recognition of fundamental labor norms. If these changes are made, it may remedy the issues that footballers are facing.

Conclusion

Diarra v. FIFA exposed a fault line between the old world of insular sports governance and the new reality where labor rights and ethical governance matter more than ever. For international sport to remain credible and fair, its legal infrastructure must shift toward transparency, equity, and respect for the individual.

Bassnectar, Settled and Still Spinning: What #MeToo Justice Leaves Behind

By: Jacqueline Purmort-LaBue

The Bassnectar case will not be going to trial. Earlier this year, Bassnectar, born Lorin Ashton, reached a private settlement with three women who had accused him of sexually abusing them when they were underage. The announcement comes shortly after his motion to dismiss was denied late last year. 

Background

The dubstep DJ and music producer became a well-known celebrity in the electronic dance music (“EDM”) scene after releasing Divergent Spectrum, his first album to hit the Billboard charts. After four years of touring and hosting specially-curated Bassnectar festivals, Ashton went on to play almost exclusively at well-known commercial festivals such as Bonnaroo, Electric Daisy Carnival, Electric Forest Festival, Lollapalooza, and Okechobee. 

In mid-2020, Ashton announced that he was stepping back from music amidst numerous accusations of sexual misconduct that surfaced on social media. The following year, Rachel Ramsbottom and Alexis Bowling filed suit, claiming to be survivors of sex trafficking and child pornography. Additionally, the lawsuit named Ashton’s management and production companies, his record label, and his charity as “knowing participants or beneficiaries” of such acts. 

Selective Justice in the #MeToo Era

Ashton is not the only celebrity who has faced charges like this. With the rise of the #MeToo movement in 2017, many women have come forward to share their experiences as survivors of sexual violence in the workplace. Although a multitude of male celebrities have been accused of sexual misconduct both within and outside the EDM community, only a handful have faced criminal or civil charges in court. Well-known names like Harvey Weinstein, Bill Cosby, R. Kelly, Kevin Spacey, and Sean “Diddy” Combs are among that handful. 

Many of these lawsuits are still in process. Some have been convicted. Others have had those convictions overturned. Only 2.5% of perpetrators will go to prison for their crimes. Frequently, survivors privately settle before the lawsuit is filed. The Rape, Abuse, and Incest National Network (“RAINN”) has reported that despite the fact that one in every six women in the U.S. experiences rape or attempted rape, five in six women who are raped do not report it. The primary reason for underreporting is a lack of trust in the policing and legal systems. 

The Bassnectar settlement includes a confidentiality agreement, meaning that there will be no details released about the settlement, no public vindication for the survivors, and no finding of wrongdoing on the part of Ashton. This raises critical legal questions: Who gets held accountable, and who gets to walk away? Why does justice still feel so selective in the post-#MeToo era?

Cancelled or Still Cashing In?

After the @EvidenceAgainstBassnectar Instagram account went live in 2020, fans have grappled with the allegations. At the time, they debated whether or not to retire their clothing featuring the famed Bassnectar bassdrop symbol, some creating altered versions meant to symbolize the community moving forward without Ashton. One fan even started a petition that has garnered nearly 2,000 signatures, calling for Ashton to give the bassdrop back to the fans and be held accountable for his actions. Many fans have elected to remove or cover up their bassdrop tattoos

The ripple effect of the allegations hasn’t just affected the fans. In October 2023, two shows were canceled at Harrah’s Cherokee Center in Asheville, North Carolina. The Gateway Center Arena in College Park, Georgia, also canceled two of his shows scheduled for April 2024 after an investigation into the allegations against Ashton. 

Ashton has spoken out publicly against cancel culture, calling it a form of “domestic terrorism” following the numerous cancellations of his shows. Since his “comeback” launched in 2023, Bassnectar has played a pair of sold-out shows in Las Vegas in October, and another pair of sold-out shows in New York City on New Year’s Eve. Clearly, not all his fans believe the allegations brought by Ramsbottom and Bowling. 

This mixed public response highlights the complexity of accountability in the digital age. While venues and some fans have taken decisive steps to distance themselves from Ashton, others continue to support him, filling arenas and defending his legacy. The split raises broader questions: Can a fan base truly separate art from artist? Is “cancel culture” a meaningful mechanism for justice, or simply a temporary disruption? As Ashton’s career presses on despite serious allegations, the Bassnectar case forces us to reckon with what accountability and fairness for survivors looks like when public opinion is so starkly divided.